PAG
AVNR

Pinnacle Advisory Group’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Pinnacle Advisory Group’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-24,500
Closed -$97K – 112
2013
Q3 		$97K Buy
+24,500
New +$116K 0.01% 101

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Pinnacle Advisory Group's AVNR Position: Q4 2013 in Review

Pinnacle Advisory Group sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2013, closing a stake of 24,500 shares — an estimated $97K sold.

Pinnacle Advisory Group first reported a position in AVNR in Q3 2013 and held it in 1 quarter. The position peaked at $97K in Q3 2013. 101 funds tracked by Wall St. Rank hold AVNR as of Q4 2013.

  • Pinnacle Advisory Group reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2013 after selling out during the quarter.
  • Pinnacle Advisory Group sold 24,500 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2013, an estimated $97K.
  • Pinnacle Advisory Group first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q3 2013 and held it in 1 quarter.
  • Pinnacle Advisory Group's AVANIR PHARMACEUTICALS, INC CL A position peaked at $97K in Q3 2013.
  • 101 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2013.

Based on Pinnacle Advisory Group's 13F filing for Q4 2013, filed 13 Feb 2014.